Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10044552HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS10052789HBVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS30073184HIVENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TVIS44024288HTLV-1ENSG00000169083.18protein_codingARYesNo367A0A087WUX9
P10275
TCGA Plot Options
Drug Information
GeneAR
DrugBank IDDB12941
Drug NameDarolutamide
Target IDBE0000132
UniProt IDP10275
Regulation Typeantagonist
PubMed IDs31571095; 28801852; 30197098
CitationsShore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K: Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.@@Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C: Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2017 Dec;80(6):1063-1072. doi: 10.1007/s00280-017-3417-3. Epub 2017 Aug 11.@@Fizazi K, Smith MR, Tombal B: Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24.
GroupsApproved; Investigational
Direct ClassificationPhenylpyrazoles
SMILESC[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O
Pathways
PharmGKB
ChEMBLCHEMBL4297185